The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation
- 26 September 2002
- journal article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 11 (7) , 569-576
- https://doi.org/10.1002/pds.748
Abstract
Purpose To determine the frequency with which atrial fibrillation (AF) patients receiving warfarin are prescribed interacting drugs that could increase bleeding risks. Methods We retrospectively examined medical records for 704 Medicare beneficiaries ≥65 years of age discharged from Kansas hospitals with AF. We identified all patients receiving warfarin and examined discharge prescriptions for drugs that could increase bleeding risk either by increasing the international normalized ratio (INR) or directly inhibiting hemostasis. Results Of 256 patients discharged on warfarin, 138 (54%) were prescribed another medication that could increase bleeding risk. Among these patients, 106 (41%) were discharged with a total of 150 prescriptions for drugs that could interact with warfarin to increase the INR. Antibiotics accounted for 67% of these prescriptions. Fifty‐three patients (21%) received 56 prescriptions for drugs which could inhibit hemostasis. These were primarily antiplatelet drugs with 61% of the prescriptions for aspirin. Patients with coronary artery disease were more likely than others to be prescribed warfarin plus antiplatelet agents (OR=2.80; p=0.04). More than one interacting drug was prescribed for 20% of the patients. Conclusions AF patients discharged on warfarin were frequently prescribed concomitant medications that increase bleeding risks. These patients should be closely monitored and counseled to watch for signs of bleeding. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
This publication has 47 references indexed in Scilit:
- Antithrombotic Therapy in Atrial FibrillationChest, 2001
- Why Do Patients With Atrial Fibrillation Not Receive Warfarin?Archives of internal medicine (1960), 2000
- Antithrombotic Therapy To Prevent Stroke in Patients with Atrial FibrillationAnnals of Internal Medicine, 1999
- Recent National Patterns of Warfarin Use in Atrial FibrillationCirculation, 1998
- Optimal Oral Anticoagulant Therapy in Patients with Mechanical Heart ValvesNew England Journal of Medicine, 1995
- Prevalence, Age Distribution, and Gender of Patients With Atrial FibrillationArchives of internal medicine (1960), 1995
- Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial FibrillationArchives of internal medicine (1960), 1994
- Clinically Significant Drug Interactions with the Oral AnticoagulantsDrug Safety, 1994
- Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor strokeThe Lancet, 1993
- Drug Interactions with WarfarinDrugs, 1983